4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at Bank of America Co. from $79.00 to $46.00. They now have a "buy" rating on the stock.
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS [Yahoo! Finance]
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now [Yahoo! Finance]
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is now covered by analysts at Morgan Stanley. They set an "underweight" rating and a $8.00 price target on the stock.